{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:09:18Z","timestamp":1760299758013,"version":"3.41.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004410","name":"Scientific and Technological Research Council of Turkey","doi-asserted-by":"publisher","award":["214Z122"],"award-info":[{"award-number":["214Z122"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ejmech.2017.12.021","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T19:02:07Z","timestamp":1513018927000},"page":"273-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Integration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on cell proliferation"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0426-0905","authenticated-orcid":false,"given":"Serdar","family":"Durdagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Busecan","family":"Aksoydan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail","family":"Erol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isik","family":"Kantarcioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yavuz","family":"Ergun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulay","family":"Bulut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melih","family":"Acar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timucin","family":"Avsar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Liapakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlasios","family":"Karageorgos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramin E.","family":"Salmas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bar\u0131\u015f","family":"Sergi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Alkhatib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gizem","family":"Turan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berfu Nur","family":"Yigit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kutay","family":"Cantasir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahar","family":"Kurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turker","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2017.12.021_bib1","series-title":"Handbook of Physiology, Microcirculation","first-page":"794","article-title":"Pathophysiology of primary hypertension","author":"Carey","year":"2008"},{"key":"10.1016\/j.ejmech.2017.12.021_bib2","series-title":"Renin Angiotensin System and Cardiovascular Disease","first-page":"59","article-title":"AT1 receptors, angiotensin receptor blockade, and clinical hypertensive disease","author":"Carey","year":"2009"},{"key":"10.1016\/j.ejmech.2017.12.021_bib3","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1016\/j.bmc.2010.10.043","article-title":"Angiotensin II receptor type 1 (AT 1) selective nonpeptidic antagonists\u2014a perspective","volume":"18","author":"Naik","year":"2010","journal-title":"Bioorg. Med. Chem."},{"year":"2013","series-title":"A\u00a0Global Brief on Hypertension: Silent Killer, Global Public Health Crisis","author":"WHO","key":"10.1016\/j.ejmech.2017.12.021_bib4"},{"key":"10.1016\/j.ejmech.2017.12.021_bib5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(24)01458-3","article-title":"International union of pharmacology. XXIII. The angiotensin II receptors","volume":"52","author":"De Gasparo","year":"2000","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2017.12.021_bib6","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10822-010-9371-3","article-title":"An efficient synthesis of a rationally designed 1, 5 disubstituted imidazole AT1 angiotensin II receptor antagonist: reorientation of imidazole pharmacophore groups in losartan reserves high receptor affinity and confirms docking studies","volume":"24","author":"Agelis","year":"2010","journal-title":"J.\u00a0Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2017.12.021_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bjc.6605866","article-title":"Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?","volume":"103","author":"Dolley-Hitze","year":"2010","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.ejmech.2017.12.021_bib8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0014-2999(95)00762-8","article-title":"Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders","volume":"297","author":"Ge","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.12.021_bib9","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1021\/jm00100a007","article-title":"New nonpeptide angiotensin II receptor antagonists. 2. Synthesis, biological properties, and structure-activity relationships of 2-alkyl-4-(biphenylylmethoxy) quinoline derivatives","volume":"35","author":"Bradbury","year":"1992","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.12.021_bib10","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0140-6736(02)08062-5","article-title":"Angiotensin blockade for hypertension: a promise fulfilled","volume":"359","author":"Brunner","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2017.12.021_bib11","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1021\/jm7011563","article-title":"Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo [3, 4-b] pyridine and related heteroaromatic bicyclic systems","volume":"51","author":"Cappelli","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.12.021_bib12","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2165\/00003495-200262080-00016","article-title":"Candesartan cilexetil","volume":"62","author":"Easthope","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2017.12.021_bib13","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1021\/jm050232e","article-title":"Design and synthesis of new tetrazolyl-and carboxy-biphenylylmethyl-quinazolin-4-one derivatives as angiotensin II AT1 receptor antagonists","volume":"49","author":"Ismail","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.12.021_bib14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0022-3565(24)38951-7","article-title":"Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding","volume":"295","author":"Maillard","year":"2000","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2017.12.021_bib15","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/jm00061a014","article-title":"Molecular shape comparison of angiotensin II receptor antagonists","volume":"36","author":"Masek","year":"1993","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.12.021_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.03.048","article-title":"Cryo-EM Structure of the Open Human Ether-\u00e0-go-go-Related K+ Channel hERG","volume":"169","author":"Wang","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2017.12.021_bib17","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1021\/ci300353u","article-title":"Modeling of open, closed, and open-inactivated states of the hERG1 channel: structural mechanisms of the state-dependent drug binding","volume":"52","author":"Durdagi","year":"2012","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2017.12.021_bib18","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1021\/ci100409y","article-title":"Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain","volume":"51","author":"Durdagi","year":"2011","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2017.12.021_bib19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1124\/jpet.111.189159","article-title":"Structure-guided topographic mapping and mutagenesis to elucidate binding sites for the human ether-a-go-go-related gene 1 potassium channel (KCNH2) activator NS1643","volume":"342","author":"Durdagi","year":"2012","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2017.12.021_bib20","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.2174\/092986710792927886","article-title":"Insights into the molecular mechanism of hERG1 channel activation and blockade by drugs","volume":"17","author":"Durdagi","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.12.021_bib21","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/prot.22815","article-title":"Structural refinement of the hERG1 pore and voltage-sensing domains with ROSETTA-membrane and molecular dynamics simulations","volume":"78","author":"Subbotina","year":"2010","journal-title":"Proteins: Structure, Function, and Bioinformatics"},{"key":"10.1016\/j.ejmech.2017.12.021_bib22","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1021\/jm060338p","article-title":"Proposal of a new binding orientation for non-peptide AT1 antagonists: homology modeling, docking and three-dimensional quantitative structure-activity relationship analysis","volume":"49","author":"Tuccinardi","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.12.021_bib23","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cell.2015.04.011","article-title":"Structure of the angiotensin receptor revealed by serial femtosecond crystallography","volume":"161","author":"Zhang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2017.12.021_bib24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Sastry","year":"2013","journal-title":"J.\u00a0Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2017.12.021_bib25","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/prot.22102","article-title":"Very fast prediction and rationalization of pKa values for protein\u2013ligand complexes","volume":"73","author":"Bas","year":"2008","journal-title":"Proteins: Structure, Function, and Bioinformatics"},{"key":"10.1016\/j.ejmech.2017.12.021_bib26","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/prot.20660","article-title":"Very fast empirical prediction and rationalization of protein pKa values","volume":"61","author":"Li","year":"2005","journal-title":"Proteins: Structure, Function, and Bioinformatics"},{"key":"10.1016\/j.ejmech.2017.12.021_bib27","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/jcc.20292","article-title":"Integrated modeling program, applied chemical theory (IMPACT)","volume":"26","author":"Banks","year":"2005","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2017.12.021_bib28","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1021\/ct200908r","article-title":"Optimization of the OPLS-AA force field for long hydrocarbons","volume":"8","author":"Siu","year":"2012","journal-title":"J.\u00a0Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2017.12.021_bib29","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10822-010-9349-1","article-title":"Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution","volume":"24","author":"Greenwood","year":"2010","journal-title":"J.\u00a0Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2017.12.021_bib30","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10822-007-9133-z","article-title":"Epik: a software program for pK a prediction and protonation state generation for drug-like molecules","volume":"21","author":"Shelley","year":"2007","journal-title":"J.\u00a0Comput. Aided Mol. Des."},{"year":"2015","series-title":"Release 2015-4: LigPrep, Version 3.6","author":"Schr\u00f6dinger","key":"10.1016\/j.ejmech.2017.12.021_bib31"},{"key":"10.1016\/j.ejmech.2017.12.021_bib32","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.12.021_bib33","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.12.021_bib34","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.12.021_bib35","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/prot.10465","article-title":"Improved protein\u2013ligand docking using GOLD","volume":"52","author":"Verdonk","year":"2003","journal-title":"Proteins: Structure, Function, and Bioinformatics"},{"year":"2016","series-title":"Molecular Operating Environment (MOE)","key":"10.1016\/j.ejmech.2017.12.021_bib36"},{"key":"10.1016\/j.ejmech.2017.12.021_bib37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10822-007-9114-2","article-title":"Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search","volume":"21","author":"Jain","year":"2007","journal-title":"J.\u00a0Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2017.12.021_bib38","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1110\/ps.062126106","article-title":"Positioning of proteins in membranes: a computational approach","volume":"15","author":"Lomize","year":"2006","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2017.12.021_bib39","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/bioinformatics\/btk023","article-title":"OPM: orientations of proteins in membranes database","volume":"22","author":"Lomize","year":"2006","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejmech.2017.12.021_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000880","article-title":"Automated builder and database of protein\/membrane complexes for molecular dynamics simulations","volume":"2","author":"Jo","year":"2007","journal-title":"PLos One"},{"key":"10.1016\/j.ejmech.2017.12.021_bib41","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1021\/acs.jctc.5b00935","article-title":"CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM simulations using the CHARMM36 additive force field","volume":"12","author":"Lee","year":"2015","journal-title":"J.\u00a0Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2017.12.021_bib42","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/jcc.23702","article-title":"CHARMM-GUI Membrane Builder toward realistic biological membrane simulations","volume":"35","author":"Wu","year":"2014","journal-title":"J.\u00a0Comput. Chem."},{"year":"2013","series-title":"GROMACS Development Team. GROMACS Version 4.6.5","author":"van der Spoel","key":"10.1016\/j.ejmech.2017.12.021_bib43"},{"key":"10.1016\/j.ejmech.2017.12.021_bib44","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/ct700301q","article-title":"GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation","volume":"4","author":"Hess","year":"2008","journal-title":"J.\u00a0Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2017.12.021_bib45","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1063\/1.448118","article-title":"Molecular dynamics with coupling to an external bath","volume":"81","author":"Berendsen","year":"1984","journal-title":"J.\u00a0Chem. Phys."},{"key":"10.1016\/j.ejmech.2017.12.021_bib46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0010-4655(95)00042-E","article-title":"GROMACS: a message-passing parallel molecular dynamics implementation","volume":"91","author":"Berendsen","year":"1995","journal-title":"Comput. Phys. Commun."},{"key":"10.1016\/j.ejmech.2017.12.021_bib47","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh Ewald: an N\u22c5 log (N) method for Ewald sums in large systems","volume":"98","author":"Darden","year":"1993","journal-title":"J.\u00a0Chem. Phys."},{"key":"10.1016\/j.ejmech.2017.12.021_bib48","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevA.31.1695","article-title":"Canonical dynamics: equilibrium phase-space distributions","volume":"31","author":"Hoover","year":"1985","journal-title":"Phys. Rev."},{"key":"10.1016\/j.ejmech.2017.12.021_bib49","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10822-006-9087-6","article-title":"PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results","volume":"20","author":"Dixon","year":"2006","journal-title":"J.\u00a0Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2017.12.021_bib50","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.bmcl.2011.12.116","article-title":"Synthesis and antihypertensive activity of pyrimidin-4 (3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT 1) antagonists","volume":"22","author":"Kim","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2017.12.021_bib51","unstructured":"Robert Cavalier, A.C., Claude Gillet, De Varebeke Philippe Janssens, Paul Niebes, Joseph Roba, Dorsser William Van, Georges Lambelin, Michel Franz. Vol. EP0130644A1 (1985)."},{"key":"10.1016\/j.ejmech.2017.12.021_bib52","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Yung-Chi","year":"1973","journal-title":"Biochem. Pharmacol."},{"year":"2004","series-title":"Fitting Models to Biological Data Using Linear and Nonlinear Regression: a Practical Guide to Curve Fitting","author":"Motulsky","key":"10.1016\/j.ejmech.2017.12.021_bib53"},{"key":"10.1016\/j.ejmech.2017.12.021_bib54","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.2174\/092986711795933731","article-title":"Strategies in the rational drug design","volume":"18","author":"Mavromoustakos","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.12.021_bib55","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1016\/j.bmcl.2013.06.041","article-title":"Development of 3D-QSAR CoMSIA models for 5-(biphenyl-2-yl)-1H-tetrazole derivatives as angiotensin II receptor type 1 (AT 1) antagonists","volume":"23","author":"Choi","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2017.12.021_bib56","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1021\/jm0610705","article-title":"The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1'position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2","volume":"50","author":"Durdagi","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.12.021_bib57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00044-015-1470-1","article-title":"3D-QSAR studies and pharmacophore identification of AT1 receptor antagonists","volume":"25","author":"Smaji\u0107","year":"2016","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2017.12.021_bib58","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/1062936X.2013.868825","article-title":"Design, synthesis, pharmacological evaluation and in silico ADMET prediction of novel substituted benzimidazole derivatives as angiotensin II\u2013AT1 receptor antagonists based on predictive 3D QSAR models","volume":"25","author":"Vyas","year":"2014","journal-title":"SAR QSAR Environ. Res."},{"key":"10.1016\/j.ejmech.2017.12.021_bib59","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejmech.2016.03.021","article-title":"N-Phenyl indole derivatives as AT 1 antagonists with anti-hypertension activities: design, synthesis and biological evaluation","volume":"115","author":"Zhu","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.12.021_bib60","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejmech.2013.08.014","article-title":"Nonpeptidic angiotensin II AT1 receptor antagonnists derived from 6-substituted aminocarbonyl and acylamino benzimidazoles","volume":"69","author":"Zhang","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.12.021_bib61","first-page":"3998","article-title":"Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells","volume":"43","author":"Sutherland","year":"1983","journal-title":"Canc. Res."},{"issue":"12","key":"10.1016\/j.ejmech.2017.12.021_bib62","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1021\/nl0483789","article-title":"Gold nanoparticles inhibit VEGF165-induced proliferation of HUVEC cells","volume":"4","author":"Bhattacharya","year":"2004","journal-title":"Nano Lett."},{"key":"10.1016\/j.ejmech.2017.12.021_bib63","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1745-7254.2008.00839.x","article-title":"Electropharmacological properties of telmisartan in blocking hKv1.5 and HERG potassium chanenls expressed on Xenopus laevis oocytes","volume":"29","author":"Tu","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2017.12.021_bib64","first-page":"240","article-title":"Structure-based design of hERG-neutral antihypertensive oxazolone and imidazolone derivatives","volume":"77","author":"Aksoydan","year":"2017","journal-title":"J.\u00a0Mol. Graph. Model"},{"key":"10.1016\/j.ejmech.2017.12.021_bib65","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2174\/0929867323666151117122116","article-title":"Leveraging NMR and X-ray data of the free ligands to build better drugs targeting GPCRs: The case of AT1R","volume":"23","author":"Kellici","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.12.021_bib66","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.bbamem.2013.12.012","article-title":"Insights into the molecular basis of action of the AT1 antagonist losartan using a combined NMR spectroscopy and computational approach","volume":"1838","author":"Zervou","year":"2014","journal-title":"BBA Biomembr."},{"key":"10.1016\/j.ejmech.2017.12.021_bib67","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1517\/13543776.2013.830104","article-title":"AT1 antagonists: A patent review (2008-2012)","volume":"23","author":"Mavromoustakos","year":"2013","journal-title":"Expert Opin. Therap. Patents"},{"key":"10.1016\/j.ejmech.2017.12.021_bib68","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ejmech.2012.07.040","article-title":"The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: A concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives","volume":"55","author":"Agelis","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.12.021_bib69","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1021\/ci800427s","article-title":"Antihypertensive drug valsartan in solution and at the AT1 receptor: conformational analysis, dynamic NMR spectroscopy, in silico docking, and molecular dynamics simulations","volume":"49","author":"Potamitis","year":"2009","journal-title":"J.\u00a0Chem. Inf. Model"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417310279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417310279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T13:54:19Z","timestamp":1751118859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523417310279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":69,"alternative-id":["S0223523417310279"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.12.021","relation":{},"ISSN":["0223-5234"],"issn-type":[{"type":"print","value":"0223-5234"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on cell proliferation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}